Table 1 MDSCs in lymphoma
From: Myeloid-derived suppressor cells in hematological malignancies: friends or foes
Disease cases (n) | MDSC subgroups/phenotype definition | Clinical finding | Mechanism/intervention | Year/reference |
|---|---|---|---|---|
NHL, n = 40 | M-MDSCs CD14+HLA-DRlow/−CD120blow | Increased M-MDSCs correlated with aggressive disease and suppressed immune functions | Restore T cell proliferation by removing NHL M-MDSC; arginase I↑ | 2011 [26] |
B-NHL, n = 42 | M-MDSCs CD14+ HLA-DRlow/− | Higher MDSCs vs. healthy donor Higher MDSCs in stage III and IV vs. stage II Higher MDSCs in relapsed/refractory patients | Arginase I↑ | 2014 [27] |
B-NHL, n = 22 | M-MDSCs CD14+ HLA-DRlow/− | Higher MDSCs with a higher IPI score | IL-10 induced M-MDSCs | 2015 [28] |
DLBCL, n = 66 | M-MDSC (CD14 + HLA-DRLow) G-MDSC (CD33 + CD11b + Lin-HLA-DR-) | Higher M/G-MDSCs vs. healthy donor M-MDSC number was correlated with the IPI, EFS, and number of circulating Tregs | Upregulated expression of IL-10, S100A12, and PD-L1 attributed to M-MDSC-dependent T cell suppression. T cell proliferation was restored after CD14+ depletion in DLBCL patients. | 2016 [29] |
T-NHL, n = 14 | M-MDSCs CD14+HLA-DRlow/− | Higher MDSCs vs. healthy donor | M-MDSCs with PD-L1 expression inhibit T cell proliferation and promote the induction of FoxP3 + Treg | 2009 [32] |
B cell (HL + NHL), n = 124 | G/PMN-MDSCs (CD66b+CD33dimHLA−DR− CD11b + CD16+) | Higher MDSCs vs. healthy donor | Restore autologous T proliferation by depletion of CD66b + cells | 2016 [33] |
Extranodal NK/T cell lymphoma (ENKL), n = 32 | Total MDSCs HLA-DR−CD33+CD11b+ M (CD14+), G (CD15+) | Higher MDSCs vs. healthy donor Total MDSCs and M-MDSCs were independent predictors for DFS and OS | Higher levels of Arg-1, iNOS, and IL-17; moderate levels of TGFβ and IL-10; but lower levels of CD66b vs. healthy donors, suppressed CD4 but not CD8 activity, inhibited IFNγ but promoted IL-10, IL-17, and TGFβ. Inhibitors of iNOS, Arg-1, and ROS restore T cell proliferation | 2015 [36] |